Cargando…

A randomized phase III study of docetaxel alone versus docetaxel plus S‐1 in patients with previously treated non‐small cell lung cancer: JMTO LC09‐01

BACKGROUND: This study evaluated the efficacy and safety of the combination chemotherapy of docetaxel plus S‐1 in patients with previously treated non‐small cell lung cancer (NSCLC) compared to docetaxel alone. METHODS: Patients with previously treated NSCLC were randomly assigned to docetaxel alone...

Descripción completa

Detalles Bibliográficos
Autores principales:	Atagi, Shinji, Daimon, Takashi, Okishio, Kyoichi, Komuta, Kiyoshi, Okano, Yoshio, Minato, Koichi, Kim, Young Hak, Usui, Ryo, Tabata, Chiharu, Tamura, Atsuhisa, Kawahara, Masaaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10569902/ https://www.ncbi.nlm.nih.gov/pubmed/37609677 http://dx.doi.org/10.1111/1759-7714.15080

Ejemplares similares

A randomized phase II study of docetaxel or pemetrexed with or without the continuation of gefitinib after disease progression in elderly patients with non‐small cell lung cancer harboring EGFR mutations (JMTO LC12‐01)
por: Asami, Kazuhiro, et al.
Publicado: (2022)

Gemcitabine and vinorelbine followed by docetaxel in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial of nonplatinum sequential triplet combination chemotherapy (JMTO LC00-02)
por: Hosoe, S, et al.
Publicado: (2003)

Standard versus low‐dose nab‐paclitaxel in previously treated patients with advanced non‐small cell lung cancer: A randomized phase II trial (JMTO LC14‐01)
por: Takeuchi, Susumu, et al.
Publicado: (2023)

Undifferentiated prostate cancer treated with docetaxel
por: Kobayashi, Masaki, et al.
Publicado: (2020)

Chrysin Increases the Therapeutic Efficacy of Docetaxel and Mitigates Docetaxel-Induced Edema
por: Lim, Hyun-Kyung, et al.
Publicado: (2016)

A Comparison of Hepatocyte Cytotoxic Mechanisms for Docetaxel and PLGA-Docetaxel Nanoparticls
por: Daraei, Bahram, et al.
Publicado: (2017)

Effects of Docetaxel Injection and Docetaxel Micelles on the Intestinal Barrier and Intestinal Microbiota
por: Liu, Qingya, et al.
Publicado: (2021)

Docetaxel-Aggravated Psoriasis
por: Yang, Seungkeol, et al.
Publicado: (2019)

Stability study of docetaxel solution (0.9%, saline) using Non-PVC and PVC tubes for intravenous administration
por: Park, Kang Hoon, et al.
Publicado: (2015)

Interstitial lung disease in gefitinib-treated Japanese patients with non-small cell lung cancer – a retrospective analysis: JMTO LC03-02
por: Nakagawa, Masatsugu, et al.
Publicado: (2009)

Chemotherapy-induced neutropenia as a prognostic factor in advanced non-small-cell lung cancer: results from Japan Multinational Trial Organization LC00-03
por: Kishida, Y, et al.
Publicado: (2009)

Docetaxel-induced photolichenoid eruption
por: Vasudevan, Biju, et al.
Publicado: (2009)

Docetaxel-related interstitial pneumonitis
por: Wang, Chung-Jen, et al.
Publicado: (2015)

Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
por: Francini, Filippo, et al.
Publicado: (2011)

Computer-aided analysis of quercetin mechanism of overcoming docetaxel resistance in docetaxel-resistant prostate cancer
por: Omoboyede, Victor, et al.
Publicado: (2023)

LC478, a Novel Di-Substituted Adamantyl Derivative, Enhances the Oral Bioavailability of Docetaxel in Rats
por: Han, Seung Yon, et al.
Publicado: (2019)

Quality-of-life evaluation for advanced non-small-cell lung cancer: a comparison between vinorelbine plus gemcitabine followed by docetaxel versus paclitaxel plus carboplatin regimens in a randomized trial: Japan Multinational Trial Organization LC00-03 (BRI LC03-01)
por: Kawahara, Masaaki, et al.
Publicado: (2011)

SCOTROC 2A: Carboplatin followed by docetaxel or docetaxel–gemcitabine as first-line chemotherapy for ovarian cancer
por: Vasey, P A, et al.
Publicado: (2006)

Docetaxel-based induction therapy prior to radiotherapy with or without docetaxel for non-small-cell lung cancer
por: Scagliotti, G V, et al.
Publicado: (2006)

Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2)
por: Rosenberg, Jonathan E., et al.
Publicado: (2018)

Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK/09/001)
por: Nicholson, S, et al.
Publicado: (2013)

Clinical pharmacodynamic factors in docetaxel toxicity
por: Puisset, F, et al.
Publicado: (2007)

Review of docetaxel in the treatment of gastric cancer
por: Tetzlaff, Eric D, et al.
Publicado: (2008)

Docetaxel: an alternative taxane in ovarian cancer
por: Katsumata, N
Publicado: (2003)

Docetaxel Retinopathy: A Case Report
por: Nghiem-Buffet, Sylvia, et al.
Publicado: (2017)

Severe Photo Toxicity Recalled by Docetaxel
por: Johansson, Emma K., et al.
Publicado: (2018)

A Case of Docetaxel-Induced Rhabdomyolysis
por: Thalambedu, Nishanth, et al.
Publicado: (2020)

Grover disease associated with docetaxel chemotherapy
por: Afvari, Shawn, et al.
Publicado: (2022)

Docetaxel-Induced Nail Bed Purpura
por: Narayanan, Arunachalam, et al.
Publicado: (2023)

SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel–irinotecan as first-line therapy for ovarian cancer
por: Clamp, A R, et al.
Publicado: (2006)

Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial
por: Joensuu, H., et al.
Publicado: (2010)

Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial
por: Tebbutt, N C, et al.
Publicado: (2013)

GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells
por: Karanika, Styliani, et al.
Publicado: (2015)

Docetaxel/S-1 Versus Docetaxel/Capecitabine as First-Line Treatment for Advanced Breast Cancer: A Retrospective Study
por: Li, Jinyu, et al.
Publicado: (2015)

The Prostate Cancer Cells Resistant to Docetaxel as in vitro Model for Discovering MicroRNAs Predictive of the Onset of Docetaxel Resistance
por: Bascetta, Lorenzo, et al.
Publicado: (2017)

Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study
por: Petrioli, R, et al.
Publicado: (2011)

Comparative In Vitro Toxicity Study of Docetaxel and Nanoxel, a Docetaxel-Loaded Micellar Formulation Using Cultured and Blood Cells
por: Do, Van Quan, et al.
Publicado: (2019)

Increased ABCC4 Expression Induced by ERRα Leads to Docetaxel Resistance via Efflux of Docetaxel in Prostate Cancer
por: Huang, Houbao, et al.
Publicado: (2020)

Preclinical studies show using enzalutamide is less effective in docetaxel-pretreated than in docetaxel-naïve prostate cancer cells
por: Lin, Changyi, et al.
Publicado: (2020)

Dose reduction of docetaxel avoids the usage of pegfilgrastim in docetaxel plus ramucirumab therapy for recurrent nonsmall cell lung cancer
por: Hamai, Kosuke, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ank0akrkn4gv3lfht9fi34dcas